Quest Partners LLC Takes Position in Harrow, Inc. (NASDAQ:HROW)

Quest Partners LLC bought a new position in Harrow, Inc. (NASDAQ:HROW) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 638 shares of the company’s stock, valued at approximately $29,000.

A number of other large investors have also added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after buying an additional 227 shares during the last quarter. nVerses Capital LLC purchased a new position in Harrow in the second quarter worth about $33,000. Allspring Global Investments Holdings LLC grew its stake in shares of Harrow by 2,730.7% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after purchasing an additional 2,048 shares during the period. Hills Bank & Trust Co purchased a new stake in shares of Harrow during the 3rd quarter valued at about $107,000. Finally, Huntington National Bank bought a new position in shares of Harrow in the 3rd quarter worth approximately $164,000. Institutional investors own 72.76% of the company’s stock.

Harrow Stock Performance

NASDAQ HROW opened at $41.91 on Monday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a twelve month low of $8.86 and a twelve month high of $59.23. The business has a 50-day moving average price of $47.61 and a 200-day moving average price of $34.69. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -44.59 and a beta of 0.76.

Analysts Set New Price Targets

A number of brokerages have commented on HROW. B. Riley reaffirmed a “buy” rating and set a $50.00 target price on shares of Harrow in a report on Thursday, August 29th. Lake Street Capital lifted their target price on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Finally, Craig Hallum raised their price objective on Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, October 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.